Site içinde arama yapın | La Lingua Nostra

bir dosya eklendi Health

2026-02-13 06:26:00 -

The "Gene-Correction" Frontier: How 2026 is Testing a One-Time Cure.

By mid-2026, the industry has officially entered the era of "In Vivo Liver Editing." This year, the focus is on Clinical Phase 1/2 Gene Therapy trials (such as BioMarin’s BMN 307 and various AAV-mediated platforms) that aim to permanently restore PAH enzyme activity in the liver. This innovation is a primary driver for the market, as patients are increasingly demanding a "One-and-Done"...

0 Yorumlar 0 hisse senetleri 15 Views 0 önizleme